Drug Profile
Hymenialdisine
Alternative Names: SKF 108752Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Anti-inflammatories; Antirheumatics; Azepines; Pyrroles; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 23 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 07 Oct 1999 New profile
- 07 Oct 1999 Preclinical development for Osteoarthritis in USA (Unknown route)